Our findings highlight the discordance of our current biomarkers—PD-L1 and TMB especially in LvM and AxM and differences in components of the immune TME between metastatic sites that merit investigation towards strategies that consider site of metastatic disease and measurements of specific immune cell infiltration. This evidence concerns the gene CD274 and metastatic neoplasm.